Genmab A/S- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Genmab A/S 公司

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Genmab A/S简介



公司代码GMAB

公司名称Genmab A/S

上市日期Oct 01, 2000

CEOVan De Winkel (Jan G.J)

员工数量2682

证券类型Depository Receipt

年结日Oct 01

公司地址Carl Jacobsens Vej 30

城市VALBY

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Denmark

邮编2500

电话4570202728

网址https://www.genmab.com/

公司代码GMAB

上市日期Oct 01, 2000

CEOVan De Winkel (Jan G.J)

Genmab A/S公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Jan G.J. Van De Winkel, Ph.D.

President, Chief Executive Officer

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

Mr. Anthony Pagano

Chief Financial Officer, Executive Vice President

--

Dr. Paolo Paoletti, M.D.

Independent Director

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Ms. Martine J. Van Vugt, Ph.D.

Executive Vice President, Chief Strategy Officer

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Mr. Rolf K. Hoffmann

Independent Director

--

Ms. Deirdre P. Connelly

Independent Chairman of the Board

--

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

名称

名称/职务

职务

持股

持股变动

Dr. Jan G.J. Van De Winkel, Ph.D.

President, Chief Executive Officer

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

Mr. Anthony Pagano

Chief Financial Officer, Executive Vice President

--

Dr. Paolo Paoletti, M.D.

Independent Director

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Ms. Martine J. Van Vugt, Ph.D.

Executive Vice President, Chief Strategy Officer

--

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Royalties

841.00M

82.29%

Net product sales

104.00M

10.18%

Milestone payments

53.00M

5.19%

Collaboration revenue

17.00M

1.66%

Reimbursement income

7.00M

0.68%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Royalties

841.00M

82.29%

Net product sales

104.00M

10.18%

Milestone payments

53.00M

5.19%

Collaboration revenue

17.00M

1.66%

Reimbursement income

7.00M

0.68%

股东统计

更新时间: 2月1日周日

持股股东

股东类型

持股股东

占比

Orbis Investment Management Ltd.

1.80%

AllianceBernstein L.P.

1.78%

Paradigm BioCapital Advisors LP

0.62%

Arrowstreet Capital, Limited Partnership

0.59%

Harding Loevner LP

0.57%

其他

94.64%

持股股东

占比

Orbis Investment Management Ltd.

1.80%

AllianceBernstein L.P.

1.78%

Paradigm BioCapital Advisors LP

0.62%

Arrowstreet Capital, Limited Partnership

0.59%

Harding Loevner LP

0.57%

其他

94.64%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

4.95%

Investment Advisor

3.48%

Hedge Fund

1.96%

Research Firm

0.19%

Pension Fund

0.03%

Bank and Trust

0.02%

Family Office

0.02%

Venture Capital

0.01%

其他

89.33%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

539

65.54M

10.64%

-9.83M

2025Q3

515

64.81M

10.54%

-15.68M

2025Q2

501

65.30M

10.31%

-6.21M

2025Q1

515

65.99M

10.42%

-5.32M

2024Q4

512

61.76M

9.33%

+621.44K

2024Q3

493

53.46M

8.41%

-4.14M

2024Q2

495

49.90M

7.86%

-6.30M

2024Q1

501

49.04M

7.53%

-7.16M

2023Q4

490

47.86M

7.32%

-6.37M

2023Q3

479

48.54M

7.43%

+204.98K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Orbis Investment Management Ltd.

11.08M

1.8%

+3.16M

+39.87%

Sep 30, 2025

AllianceBernstein L.P.

10.95M

1.78%

+291.54K

+2.73%

Sep 30, 2025

Paradigm BioCapital Advisors LP

3.82M

0.62%

+3.82M

--

Sep 30, 2025

Arrowstreet Capital, Limited Partnership

3.64M

0.59%

+188.76K

+5.46%

Sep 30, 2025

Harding Loevner LP

3.48M

0.57%

+561.05K

+19.19%

Sep 30, 2025

Two Sigma Investments, LP

2.82M

0.46%

-615.53K

-17.90%

Sep 30, 2025

Renaissance Technologies LLC

2.82M

0.46%

+54.79K

+1.98%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

2.61M

0.42%

+101.63K

+4.06%

Sep 30, 2025

First Trust Advisors L.P.

1.69M

0.27%

-82.92K

-4.68%

Sep 30, 2025

Parametric Portfolio Associates LLC

1.58M

0.26%

+391.90K

+32.97%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Tema Oncology ETF

4.2%

First Trust NYSE Arca Biotechnology Index Fund

3.02%

WisdomTree BioRevolution Fund

1.31%

iShares Biotechnology ETF

1.15%

AB Disruptors ETF

0.69%

JPMorgan Healthcare Leaders ETF

0.28%

First Trust NASDAQ BuyWrite Income ETF

0.26%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.12%

ActivePassive International Equity ETF

0.12%

Tema Oncology ETF

占比4.2%

First Trust NYSE Arca Biotechnology Index Fund

占比3.02%

WisdomTree BioRevolution Fund

占比1.31%

iShares Biotechnology ETF

占比1.15%

AB Disruptors ETF

占比0.69%

JPMorgan Healthcare Leaders ETF

占比0.28%

First Trust NASDAQ BuyWrite Income ETF

占比0.26%

ProShares Ultra Nasdaq Biotechnology

占比0.12%

Invesco Nasdaq Biotechnology ETF

占比0.12%

ActivePassive International Equity ETF

占比0.12%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据